Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by the formation of scar tissue (fibrosis) in the lungs. This scarring stiffens the lung tissue, making it difficult to breathe and leading to low oxygen levels. While there is currently no cure that reverses existing damage, modern medicine offers a robust toolkit to slow disease progression, manage debilitating symptoms, and significantly improve quality of life.
Treatment is highly personalized. As soon as a diagnosis is confirmed, healthcare teams—typically led by pulmonologists—evaluate the severity of the disease, its rate of progression, and the patient’s overall health to create a tailored care plan.
“IPF treatment starts as soon as the diagnosis is confirmed,” explains Dr. Kenneth D’Souza, a pulmonologist and medical director at Mercy Health in Cincinnati. The goal is not just to treat the lungs, but to support the whole person through medication, lifestyle adjustments, and, in some cases, surgery.
The Core Defense: Antifibrotic Medications
The cornerstone of IPF treatment lies in a class of drugs known as antifibrotics. These medications do not heal existing scars; instead, they work to slow the rate at which new scar tissue forms, thereby preserving lung function for longer.
Currently, three antifibrotic drugs are approved by the U.S. Food and Drug Administration (FDA):
- Nintedanib (Ofev)
- Pirfenidone (Esbriet)
- Nerandomilast (Jascayd)
A Breakthrough After a Decade
For over ten years, only two options were available. However, in 2025, the FDA approved nerandomilast, marking the first new IPF treatment in more than a decade. According to Dr. Guillermo Garrido of Orlando Health, this drug operates via a different biological mechanism than its predecessors. It is particularly significant for patients who cannot tolerate the side effects of nintedanib or pirfenidone, offering a crucial alternative for maintaining therapy adherence.
Managing Side Effects
Antifibrotics are effective but often come with gastrointestinal and systemic side effects. Patients may experience:
* Diarrhea, nausea, or vomiting
* Loss of appetite or weight loss
* Fatigue, headache, or dizziness
* Elevated liver enzymes (requiring regular blood monitoring)
* Sun sensitivity or skin rashes (specifically with pirfenidone)
Healthcare providers closely monitor these reactions, often adjusting doses or timing to help patients stay on the medication.
Managing Acute Flare-Ups and Symptoms
Beyond slowing fibrosis, treatment plans address immediate symptoms and complications that affect daily living.
Corticosteroids for Acute Exacerbations
IPF can suffer from “acute exacerbations”—sudden, severe worsening of symptoms. In these critical moments, doctors may prescribe short-term corticosteroids (such as prednisone or methylprednisolone ) to reduce lung inflammation.
* Why it matters: While evidence for long-term benefit is limited, steroids can be life-saving during a flare-up.
* Side effects: Potential issues include weight gain, insomnia, high blood pressure, mood changes, and increased infection risk.
Addressing Acid Reflux (GERD)
There is a strong link between IPF and gastroesophageal reflux disease (GERD). When stomach acid flows back into the esophagus, tiny amounts can be inhaled into the lungs (micro-aspiration), irritating lung tissue and worsening cough or shortness of breath.
* Treatment: Proton pump inhibitors (like omeprazole or esomeprazole ) or H2 blockers (like famotidine ) are used to control acid production.
* Goal: While these drugs do not treat IPF directly, managing reflux can reduce lung irritation and potentially slow symptom progression.
Controlling the Cough
A persistent, dry cough is one of the most distressing symptoms of IPF. Standard cough medicines often fail, but doctors may trial suppressants such as:
* Dextromethorphan (found in Delsym, Robitussin)
* Benzonatate (Tessalon Perles)
Finding the right relief often requires patience and experimentation under medical supervision.
The Surgical Option: Lung Transplantation
For eligible patients, a lung transplant remains the only potential cure for IPF. This major surgery replaces diseased lungs with healthy donor organs.
Early Evaluation is Key
Guidelines recommend that transplant evaluation begin as soon as IPF is diagnosed. This is not because surgery is imminent, but because the evaluation process is complex and time-consuming. Early assessment ensures patients are aware of their options before the disease progresses too far.
Who is a candidate?
* Typically under age 70 (though criteria are flexible based on biological age).
* Good health outside of lung disease (heart, kidney, and liver function must be stable).
* Strong social support system and mental readiness for lifelong post-transplant care.
* Commitment to lifelong immunosuppressive medication to prevent organ rejection.
For many, a transplant offers extended survival and improved quality of life. For others, the surgical risks may outweigh the benefits. This is a deeply personal decision made in consultation with a specialized care team.
Lifestyle Modifications: Protecting Lung Health
While lifestyle changes cannot reverse fibrosis, they play a vital role in managing symptoms and preventing secondary complications. Experts recommend the following proactive steps:
- Quit Smoking Immediately: This includes cigarettes, vaping, marijuana, and any other inhaled irritants. Smoking accelerates lung damage.
- Vaccinations: Stay current on flu and pneumonia vaccines to prevent respiratory infections, which can be devastating for IPF patients.
- Stay Active: Regular, gentle exercise (like walking) helps maintain stamina and can reduce the sensation of breathlessness.
- Nutrition and Weight Management: Maintaining a healthy weight reduces the work of breathing. A balanced diet supports energy levels and overall immunity.
- Avoid Irritants: Minimize exposure to dust, fumes, pollution, and strong chemical odors.
- Manage Comorbidities: Effectively treating conditions like sleep apnea, diabetes, or heart disease is essential for overall lung health.
Key Questions for Your Healthcare Team
To ensure you are getting the most comprehensive care, consider discussing these topics with your doctor:
- New Medications: “Am I a candidate for the newly approved medication nerandomilast, especially if I have had side effects from other drugs?”
- Transplant Eligibility: “Should I be referred for a lung transplant evaluation now, regardless of my current severity?”
- Oxygen Therapy: “At what point should we consider supplemental oxygen to help with daily activities?”
- Rehabilitation: “Would pulmonary rehabilitation be beneficial for me, and how do I get started?”
- Clinical Trials: “Are there any emerging clinical trials I might be eligible for?”
The Bottom Line
While idiopathic pulmonary fibrosis is a serious condition, it is no longer a diagnosis without hope. Antifibrotic medications like nintedanib, pirfenidone, and the newly approved nerandomilast offer proven ways to slow disease progression. Combined with symptom management for cough and reflux, lifestyle adjustments, and early consideration of lung transplantation, patients can maintain a higher quality of life for longer.
The most effective approach is proactive: engage with your healthcare team early, stay informed about new treatments, and prioritize lung-protective habits every day.
